Affimed Gmbh

Amphivena Therapeutics, Inc.

Affimed Therapeutics, Ag

University of the Witwatersrand, Johannesburg

Affemed Gmbh

Affirmed Gmbh

Ludwig-maximilians-universitat München

Uwe Reusch

Stefan Knackmuss

Kristina Ellwanger

Ivica Fucek

Erich Rajkovic

Melvyn Little

Martin Treder

Michael Weichel

Eugene Zhukovsky

Thorsten Ross

Fabrice Le Gall

Vera Molkenthin

Sergey Kipriyanov

Luke Evnin

Jeanmarie Guenot

Lori Kunkel

Judith A Fox

Karin Hoffmann

Michael Tesar

Claudia Wall

Peter Röttgen

Michael Kluge

Michael Damrat

Joachim Koch

Stefan Franz Thomas Weiss

Marc Saul Weinberg

Adelheid Cerwenka

Katarina Jovanovic

Thomas Mueller

Jens Pahl

Jens-Peter Marschner

Claudia Büttner

Clémence Rey

Vera Mick

Markus Eser

Melvin Little

Fionnuala McAleese-Eser

Bianca Da Costa Dias

Danielle Gonsavles

Stefan Weiss

Sergej Kiprijanov

Stefan H J Knackmuss

MSergey Kipriyanov

Holger J Dulat

Stefan Hans Knackmuss

Eugene Zhukovksy

Fionnuala Mcaleese-Eser

Thorsten Gantke

The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.

Tandem diabody for CD16A-directed NK-cell engagement

Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.

Bispecific EGFR/CD16 antigen-binding protein

The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS.and).

Multivalent FV antibodies

The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.

Combination of an anti-CD16A antibody with a cytokine

Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.

Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy

The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc&#x3b3;RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.

NK cell engaging antibody fusion constructs

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33cancers, diseases and conditions such as acute myeloid leukemia (AML).

Bispecific CD33 and CD3 binding proteins

This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3. Further described are highly cytotoxic EGFRvIII/CD3 bispecific tandem diabody for recruiting T cells to specifically and potently kill several types of solid tumor cancer.

Antibody binding sites specific for EGFRvIII

The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.

CD3 binding domains

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc&#x3b3;RIIIA), and in particular binding molecules that specifically bind the A form Fc&#x3b3;RIII but do not bind to the B form of Fc&#x3b3;RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.

Anti-CD16 binding molecules

The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (&#x3b2;) and gamma (&#x3b3;) secretases and amyloid beta peptide (A&#x3b2;), and also relates to a method of reducing A&#x3b2; shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.

Compounds for use in the treatment of Alzheimer's disease

Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for the human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Pharmaceutical compositions containing any of the above mentioned polynucleotides, antibodies or vectors are useful for immunotherapy, preferably against acute transplant rejections.

Human CD3-specific antibody with immunosuppressive properties

Growing community of inventors

Maikammer, Germany

Uwe Reusch